We are excited to see everyone at the #IOSummit this week in Philly. Come learn from expert - Mike Schmidt, CSO - on August 8th, as he will be presenting and sharing ways to accelerate #bispecifics discovery. While you are at the conference, swing by Booth 12 to chat with the team, Scott McMenemy, and explore more ways to accelerate your antibody-based therapeutic pipeline! #antibodydiscovery #makemedicinetogether #maythebestdrugwin
Alloy Therapeutics, Inc.
Biotechnology Research
Boston, Massachusetts 15,902 followers
May The Best Drug Win
About us
Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. From licensing our platforms, to working with us as a trusted discovery service partner, we have collaborated with over 170 partners and counting including 18 of Fortune 50 Biopharmaceutical companies to enable the discovery of their next breakthrough biologic medicines. With Alloy, you can: • Access our ever-growing stable of antibody and bispecific discovery platforms that blend in vivo and in vitro wet-lab capabilities with AI/ML. Discover with us through our services or by licensing our technologies for use in your lab. • Unlock intracellular targets with the therapeutic potential of T cell receptor (TCR) modalities through our fully integrated Keyway™ TCRm discovery service offering. • Reach genetic disease targets at the nucleic acid level with our novel AntiClastic™ ASO Format, which enhances the molecule's potency while minimizing off-target interaction and inflammatory response. • Co-build new biotechnology companies that leverage our core platforms and service capabilities with Alloy's affiliated Venture Studio, 82VS. Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Boston, MA, with labs in Cambridge, U.K.; Basel, CH; and Athens, GA. We reinvest 100% of our revenue back into innovation and access to innovation. Reach out, follow, and visit our website, to learn more about how we can make better medicines, together. https://www.alloytx.com/
- Website
-
http://www.alloytx.com
External link for Alloy Therapeutics, Inc.
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Boston, Massachusetts
- Type
- Privately Held
- Founded
- 2017
- Specialties
- Biologics Discovery, Drug Discovery, Monoclonal Antibodies, Bispecific Antibodies, TCR, RNA, ASO, Chimeric Antigen Receptors, Immunotherapy, Humanized Transgenic Mouse, Biotechnology, Biotech, Venture Studios, and Company Creation
Locations
-
Primary
44 Hartwell Ave
Boston, Massachusetts 02421, US
-
The McClintock Building, Granta Park
Suite 3
Cambridge, CB216GP CB216GP, GB
Employees at Alloy Therapeutics, Inc.
-
Bill Lesieur
AI Revolution | Open Innovation | CVC | Future of Work | Equitable Futures | Sustainability | Corporate Innovation | Futurist | Strategic Foresight |…
-
Martin Leach, PhD, MBA
Global biotech COO leveraging and improving business operations through data science, analytics, machine learning, and AI to fuel and accelerate…
-
Richard Shimkets
-
Errik Anderson
CEO and Founder at Alloy Therapeutics, Inc. and General Partner at 82VS
Updates
-
Alloy Therapeutics, Inc. reposted this
Success in both rugby and the therapeutics industry relies heavily on teamwork, strategy, and resilience. Just as a rugby team coordinates its players, leverages each individual's strengths, and adapts to challenges on the field, a successful therapeutics company like Alloy Therapeutics thrives by fostering a collaborative culture, harnessing diverse expertise, and navigating the complex landscape of drug development. In rugby, every player understands their role and works towards a common goal, whether it's scoring a try or defending their line. Similarly, in a therapeutics company, each team member, from researchers to business developers, plays a crucial part in bringing innovative treatments to patients. The ability to pivot strategies in response to opponents on the field mirrors how biotech firms must adapt to scientific discoveries, regulatory hurdles, and market dynamics. Moreover, the resilience seen in rugby players, who push through physical and mental barriers, is akin to the determination required in the therapeutics field, where setbacks are common, and persistence is key to breakthroughs. Both arenas demand a relentless pursuit of excellence and a commitment to the team's mission. At Alloy Therapeutics, we draw inspiration from the teamwork, strategy, and resilience that define a successful rugby team like the New England FreeJacks as we strive to make a meaningful impact in making therapeutic drugs. 🏉💡 #Teamwork #Innovation #Healthcare #Rugby #AlloyTherapeutics
-
-
Alloy Therapeutics, Inc. reposted this
CMT Research Foundation recently hosted a webinar featuring Dr. Jorge A. Quiroz (NMD Pharma A/S), Dr. Carlos Loya (82VS, an Alloy Therapeutics, Inc. Venture Studio) and Peter J. de Silva (CMTRF Board Chair and ENDGAME Chair). The webinar highlighted two major events that are underway for CMT. Dr. Quiroz spoke about NMD Pharma receiving approval to initiate a Phase 2 clinical trial of NMD670 in patients living with CMT types 1 and 2. Dr. Loya spoke about a new technology for CMT drug development and highlighted the delivery vehicle designed to carry genetic therapies to the peripheral nervous system. View the webinar here: https://lnkd.in/gCm_7Fzi To learn more about ENDGAME, a campaign to raise $10 million to fund critically urgent research to overcome key remaining barriers and to pave the way for clinical trials, treatments and cures for CMT1A, visit www.cmtrf.org/endgame
CMT1A Clinical Trial and Drug Development Update
https://www.youtube.com/
-
Alloy Therapeutics, Inc. reposted this
We are looking for a highly motivated Oligo chemist to join our innovative team at Alloy to work on our novel “AntiClastic” RNA Medicine Creation Platform. AntiClastic platform has a broad range of applications including the fields of antisense therapeutics, immunomodulating oligonucleotides, and other RNA therapeutic modalities. It is a unique opportunity, join us and be part of a company where your ideas are valued and encouraged. Feel free to share this opportunity with your network.
-
Alloy Therapeutics, Inc. reposted this
Pleased to share new valuable partnerships supporting up to 6 biotech founders through the Mission BioCapital Platinum Program! Apply now for everything you need to launch your company: $500K, lab space, drug discovery services, legal advisory services, accounting services, and mentoring! Alloy Therapeutics, Inc., BioLabs, Eli Lilly and Company, Goodwin, LabCentral, MBC BioLabs, Ono Venture Investment, van den Boom & Associates LLC
And the Platinum Program keeps getting better! We’re happy to share that in addition to capital, lab space, drug discovery services and mentoring, you can now also win legal and accounting services from Goodwin and van den Boom & Associates LLC, respectively. We love working with these partners and know you will, too. Learn more and apply today at https://bit.ly/3FoTf45!
-
-
Last week we hosted our first ever Alloy R&D Day in Kendall Square, and it was so great to see many of our friends and partners together! Special thank you to our guest participants: Sudhir Agrawal D.Phil, FRSC, Paul Yaworsky, Jennifer Griffin, William LaRochelle, Catherine Sabatos-Peyton, and Ryan Rust, PharmD, MBA. See you all next year! #makemedicinetogether
-
-
-
-
-
2
-
-
Last chance to sign up for Alloy R&D Day, we look forward to seeing everyone next week in Cambridge!
We are thrilled to be hosting our first ever Alloy Therapeutics, Inc. R&D Day on Thursday, June 13th in Cambridge, MA ! Please fill out the following form if you would like to receive more information about the event: https://lnkd.in/eh9DkHjR
-
For those at BIO International Convention this week stop by Booth 4955 to learn more about how we are accelerating the translation of therapeutic antibody programs from target to lead candidate to CMC with Alloy Therapeutics, Inc. and Wheeler Bio, Inc.! #makemedicinetogether #maythebestdrugwin
-
-
We are exited to unveil Wheeler No. 3 to commemorate our exciting partnership with Wheeler Bio, Inc. to accelerate the path for antibody based therapeutics from discovery to GMP manufacturing! We'll be at BIO International Convention next week also at booth 4955. Stop by to try the Wheeler No. 3 beer and learn more!
Yes… another one! Looking forward to the BIO International Convention 2024! Wheeler Bio, Inc. will be exhibiting at Booth #4955 in the Bioprocess Zone. We had fun collaborating with Alloy Therapeutics, Inc. to celebrate our ongoing partnership around integrating ATX Gx and their Antibody Discovery Services with our Portable CMC® antibody manufacturing platform. Thanks to Russell Beckerman for his inspiration on the label art and clone recipe- a la Heady Topper! Wheeler No. 3 is a delicious New England DIPA brewed by Roughtail Brewing Company in Edmond, OK. Shout out to Blake N. Behrens at Rad Five Creative for killer label art. I hope to see you at our booth in two weeks!
-
-
Alloy Therapeutics, Inc. reposted this
Global biotech COO leveraging and improving business operations through data science, analytics, machine learning, and AI to fuel and accelerate innovation
I'm so pleased to announce that I have a position to expand my Operations Team working in support of our Gx Transgenic Mouse Platform. https://lnkd.in/ga3YMrgS This is a great entry-level position that will be working with a world-class team, bringing the latest ground-breaking transgenic mice to our partners for antibody discovery! We have a great, close-knit team, and this is a terrific opportunity to learn from industry veterans and experts in drug discovery!